Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients

HIV Medicine

Volumn 12, Issue 7, 2011, Pages 442-446

  Briz, V ^a   Palladino, C ^a   Navarro, M L ^a   Jimenez de Ory S ^a   Gonzalez Tome M I ^b   León, Ja ^c   Nunez Cuadros E ^d   de Jose M I ^e   Ramos, Jt ^f   Munoz Fernandez M A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Adolescents; Children; Etravirine; Highly active antiretroviral therapy; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRIDAZINES; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 79959975874     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00907.x     Document Type: Article

References (12)

1. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009 (pp. 113-139). Available at (accessed 10 January 2010).
2. Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-2300.
3. Eron J, Haubrich R, Reiss P et al. Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 2009 [Abstract MOPEB043].
4. Mills A, Cahn P, Molina J, Nijs S, Vingerhoets J, Witek J. Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 2009 [Abstract MOPEB036].
5. TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents. Available at (accessed 15 April 2010).
6. TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents. Available at (accessed 15 April 2010).
7. Königs C, Feiterna-Sperling C, Esposito S et al. Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Abstract 879].
8. Stanford University HIV Drug Resistance Database. Available at (accessed 28 February 2010).
9. Garcia-Merino I, de Las Cuevas N, Jimenez JL et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 2009; 6: 27.
10. Vaz P, Chaix ML, Jani I et al. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure. Pediatr Infect Dis J 2009; 28: e283-e287.
11. Maiga AI, Descamps D, Morand-Joubert L et al. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes. Antimicrob Agents Chemother 2010; 54: 728-733.
12. Thuret I, Chaix ML, Tamalet C et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS 2009; 23: 2364-2366.